Trial Results

Protocol
Available Languages: English
Statistical Analysis Plan
Available Languages: English

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

Study Identifier:
ALXN1210-NMO-307
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Biological: Ravulizumab
Date
Dec 2019 - Mar 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 100 Years
Requirements Information
Sex
Female & Male
Age
18 - 100 Years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Biological: Ravulizumab
Date
Dec 2019 - Mar 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 100 Years years
Requirements Information

Protocol Summary

The primary purpose of this study is to evaluate the efficacy and safety of ravulizumab for the treatment of adult participants with NMOSD.

Trial Locations

Location
Status
Location
Research Site
Aurora, Colorado, United States, 80045
Status
N/A
Location
Research Site
Fort Collins, Colorado, United States, 80528
Status
N/A
Location
Research Site
Washington, District of Columbia, United States, 20007
Status
N/A
Location
Research Site
Miami, Florida, United States, 33136
Status
N/A
Location
Research Site
Boston, Massachusetts, United States, 02114
Status
N/A
Location
Research Site
Rochester, Minnesota, United States, 55905
Status
N/A